134 related articles for article (PubMed ID: 9788600)
1. Inhibition of growth and proliferation of EcRG293 cell line expressing high-affinity gonadotropin-releasing hormone (GnRH) receptor under the control of an inducible promoter by GnRH agonist (D-Lys6)GnRH and antagonist (Antide).
Kakar SS
Cancer Res; 1998 Oct; 58(20):4558-60. PubMed ID: 9788600
[TBL] [Abstract][Full Text] [Related]
2. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract][Full Text] [Related]
3. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of growth and down-regulation of gonadotropin releasing hormone (GnRH) receptor in alphaT3-1 cells by GnRH agonist.
Kakar SS; Nath S; Bunn J; Jennes L
Anticancer Drugs; 1997 Apr; 8(4):369-75. PubMed ID: 9180390
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha.
Wu HM; Cheng JC; Wang HS; Huang HY; MacCalman CD; Leung PC
Cancer Res; 2009 May; 69(10):4202-8. PubMed ID: 19366794
[TBL] [Abstract][Full Text] [Related]
6. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor.
Maudsley S; Davidson L; Pawson AJ; Chan R; López de Maturana R; Millar RP
Cancer Res; 2004 Oct; 64(20):7533-44. PubMed ID: 15492280
[TBL] [Abstract][Full Text] [Related]
8. Binding of agonist but not antagonist leads to fluorescence resonance energy transfer between intrinsically fluorescent gonadotropin-releasing hormone receptors.
Horvat RD; Roess DA; Nelson SE; Barisas BG; Clay CM
Mol Endocrinol; 2001 May; 15(5):695-703. PubMed ID: 11328852
[TBL] [Abstract][Full Text] [Related]
9. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.
Castellón E; Clementi M; Hitschfeld C; Sánchez C; Benítez D; Sáenz L; Contreras H; Huidobro C
Cancer Invest; 2006; 24(3):261-8. PubMed ID: 16809153
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of gonadotrophin-releasing hormone (GnRH) on rat granulosa cell deoxyribonucleic acid synthesis.
Saragüeta PE; Lanuza GM; Barañao JL
Mol Reprod Dev; 1997 Jun; 47(2):170-4. PubMed ID: 9136118
[TBL] [Abstract][Full Text] [Related]
11. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
12. The role of gonadotropin-releasing hormone (GnRH) and its receptor in development of porcine preimplantation embryos derived from in vitro fertilization.
Nam DH; Lee SH; Kim HS; Lee GS; Jeong YW; Kim S; Kim JH; Kang SK; Lee BC; Hwang WS
Theriogenology; 2005 Jan; 63(1):190-201. PubMed ID: 15589284
[TBL] [Abstract][Full Text] [Related]
13. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
[TBL] [Abstract][Full Text] [Related]
14. Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP.
Ravenna L; Salvatori L; Morrone S; Lubrano C; Cardillo MR; Sciarra F; Frati L; Di Silverio F; Petrangeli E
J Androl; 2000; 21(4):549-57. PubMed ID: 10901441
[TBL] [Abstract][Full Text] [Related]
15. Evidence that gonadotropin-releasing hormone (GnRH) II stimulates luteinizing hormone and follicle-stimulating hormone secretion from monkey pituitary cultures by activating the GnRH I receptor.
Okada Y; Murota-Kawano A; Kakar SS; Winters SJ
Biol Reprod; 2003 Oct; 69(4):1356-61. PubMed ID: 12801988
[TBL] [Abstract][Full Text] [Related]
16. GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells.
Eicke N; Günthert AR; Emons G; Gründker C
Int J Oncol; 2006 Nov; 29(5):1223-9. PubMed ID: 17016655
[TBL] [Abstract][Full Text] [Related]
17. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
Gründker C; Emons G
Reprod Biol Endocrinol; 2003 Oct; 1():65. PubMed ID: 14594454
[TBL] [Abstract][Full Text] [Related]
18. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats.
Anderes KL; Luthin DR; Castillo R; Kraynov EA; Castro M; Nared-Hood K; Gregory ML; Pathak VP; Christie LC; Paderes G; Vazir H; Ye Q; Anderson MB; May JM
J Pharmacol Exp Ther; 2003 May; 305(2):688-95. PubMed ID: 12606616
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
Fister S; Günthert AR; Emons G; Gründker C
Cancer Res; 2007 Feb; 67(4):1750-6. PubMed ID: 17308117
[TBL] [Abstract][Full Text] [Related]
20. Proliferation of TSU-Pr1, a human prostatic carcinoma cell line is stimulated by gonadotropin-releasing hormone.
Enomoto M; Seong JY; Kawashima S; Park MK
Life Sci; 2004 May; 74(25):3141-52. PubMed ID: 15081579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
